Skip to main content

Table 1 Clinical and epidemiological characteristics of individuals in the study

From: Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control

Patient

Gender

Age (years)

Year of HIV diagnosis

Years of HIV suppression

Exposure category

Median CD4+ T cells (cells/mm3)

Median CD8+ T cells (cells/mm3)

Viral load frequency (%)

(IQR)

(IQR)

< 80a

81–400a

401–5000a

EC02

Female

52

1997

15

HET

1229

(1088–1443)

1539

(1406–1741)

100

  

EC17

Female

65

2000

15

NI

1771

(1505–2134)

836

(693–994)

90

10

 

EC52

Female

43

1997

18

HET

1263

(1056–1420)

485

(423–540)

100

  

EC11

Female

48

1995

20

HET

1078

(987–1218)

965

(806–1168)

92

 

8

EC18

Female

82

2001

9

HET

809

(675–940)

666

(594–761)

87

13

 

EC42

Female

61

1993

22

HET

974.5

(871–1133)

734

(515–933)

74

26

 

VC05

Male

51

1991

24

NI

1278

(1114–1461)

857

(645–1009)

16

47

17

VC06

Male

37

2000

11

MSM

1093

(929–1222)

1112

(870–1224)

42

50

8

VC14

Female

45

1999

16

HET

701.5

(652–767)

657

(585–749)

55

36

9

VC15

Female

41

2001

14

HET

703

(677–826)

894

(755–1002)

  

100

VC16

Male

48

1998

17

MSM

563

(528–637)

837

(719–958)

21

37

32

Patient

Genotype HLA-B

Genotype CCR5

Early visit date

Later visit date

Difference VE × VL (months)

EC02

B*48, B*52

WT/WT

NOV/08

AUG/12

45

EC17

B*07, B*40

WT/WT

SEP/09

OCT/13

49

EC52

B*45, B*57

WT/WT

FEB/09

AUG/13

54

EC11

B*49, B*81

WT/∆32

DEC/09

APR/12

28

EC18

B*07, B*52

WT/WT

OCT/09

SEP/10

11

EC42

B*15, B*51

WT/WT

DEC/09

NOV/14

59

VC05

B*15, B*52

WT/WT

FEB/09

JUN/13

52

VC06

B*15, B*48

WT/∆32

JAN/09

MAY/11

28

VC14

B*42, B*44

WT/WT

APR/09

NOV/14

67

VC15

B*56, B*57

WT/WT

AUG/09

FEB/13

42

VC16

B*14, B*57

WT/WT

SEP/09

SEP/14

60

  1. aCopies/ml
  2. HET heterosexual, NI non-Informed, MSM men who have sex with men, IQR interquartile range, WT wild-type, HLA-B protective alleles are in italic